Cigna's AI investments aim to save $200 million by improving chronic disease detection and reducing paperwork
Cigna's chief data and AI officer, Katya Andresen, is shifting the focus from 'how to use AI' to 'how to lead in an age of AI.' The company projects that its AI tools for identifying chronic conditions will save $200 million over three years, and it is investing $100 million to cut clinician documentation time. A targeted campaign using AI insights encouraged over 80% of patients to switch to cheaper biosimilars.
Cigna’s AI-driven chronic condition detection spans cancer, kidney disease, and high-risk pregnancy, with projected savings of $200 million over three years by linking patients to clinicians earlier. Separately, a $100 million investment through 2028 targets reducing clinician documentation time and speeding prescriptions. The biosimilar campaign, based on analyzing thousands of past customer conversations, pushed over 80% of targeted patients to cheaper alternatives, yielding hundreds of millions in patient savings while improving margins. Cigna’s regulatory framework, built over a decade for machine learning, provides existing governance for these tools.
This push could reshape how insurers balance cost control with patient care, potentially lowering premiums or out-of-pocket costs for chronic conditions. However, reliance on AI for clinical decisions may raise concerns about data privacy and misdiagnosis, especially as millions already use chatbots for health advice. The measurable savings could pressure competitors to adopt similar tools, but outcomes depend on guardrails and transparency.